Z 
Zimmer Biomet Holdings ZBH · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
108.33
+2.59%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$8.23bn
FY2016FY2025
Net income
$705.2m
FY2016FY2025
Free cash flow
$1.47bn
FY2016FY2025
Shareholders' equity
$12.70bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.23bn | $7.68bn | $7.39bn | $6.94bn | $6.83bn | $6.13bn | $7.98bn | $7.93bn | $7.80bn | $7.67bn |
| Gross profit | $5.07bn | $5.49bn | $5.31bn | $4.92bn | $4.87bn | $4.30bn | $5.73bn | $5.66bn | $5.67bn | $5.29bn |
| Research and development | $458.5m | $437.4m | $458.7m | $406.0m | $435.8m | $322.8m | $449.3m | $391.7m | $369.9m | $365.6m |
| Operating income | $1.12bn | $1.29bn | $1.28bn | $696.3m | $860.3m | $83.1m | $1.13bn | $33.8m | $799.3m | $821.1m |
| Net income | $705.2m | $903.8m | $1.02bn | $231.4m | $401.6m | −$138.9m | $1.13bn | −$379.2m | $1.81bn | $305.9m |
| Diluted earnings per share | 3.56 | 4.52 | 4.91 | 1.10 | 1.92 | -0.66 | 5.45 | -1.84 | 8.89 | 1.51 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $23.09bn | $21.37bn | $21.50bn | $21.07bn | $23.46bn | $24.42bn | $24.64bn | $24.13bn | $26.01bn | $26.68bn |
| Cash and short-term investments | $591.9m | $525.5m | $415.8m | $375.7m | $378.1m | $802.1m | $617.9m | $542.8m | $524.4m | $634.1m |
| Total liabilities | $10.39bn | $8.89bn | $9.01bn | $9.04bn | $10.79bn | $12.22bn | $12.25bn | $12.85bn | $14.28bn | $17.01bn |
| Debt | $7.52bn | $6.20bn | $5.77bn | $5.70bn | $7.07bn | $8.13bn | $8.21bn | $8.92bn | $10.14bn | $11.24bn |
| Shareholders' equity | $12.70bn | $12.47bn | $12.48bn | $12.02bn | $12.66bn | $12.19bn | $12.39bn | $11.27bn | $11.74bn | $9.67bn |
| Shares outstanding | 198m | 200m | 209m | 210m | 209m | 209m | 208m | 206m | 204m | 203m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $1.70bn | $1.50bn | $1.58bn | $1.28bn | $1.50bn | $1.20bn | $1.59bn | $1.75bn | $1.58bn | $1.63bn |
| Capital spending | −$224.5m | −$356.8m | −$394.5m | −$187.9m | −$152.0m | −$117.9m | −$404.7m | −$162.7m | −$156.0m | −$184.7m |
| Free cash flow | $1.47bn | $1.14bn | $1.19bn | $1.10bn | $1.35bn | $1.09bn | $1.18bn | $1.58bn | $1.43bn | $1.45bn |
| Dividends paid | −$190.3m | −$196.0m | −$200.9m | −$201.2m | −$200.1m | −$198.5m | −$196.7m | −$195.2m | −$193.6m | −$188.4m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.18bn | $2.09bn | $2.24bn | $2.00bn | $2.08bn | $1.91bn | $2.02bn | $1.82bn |
| Gross profit | $1.54bn | $1.51bn | $1.45bn | $1.44bn | $1.49bn | $1.36bn | $1.44bn | $1.29bn |
| Operating income | $326.1m | $373.2m | $169.9m | $351.3m | $300.0m | $292.3m | $389.0m | $279.5m |
| Net income | $198.3m | $238.1m | $139.5m | $230.9m | $152.8m | $182.0m | $239.5m | $249.1m |
| Diluted earnings per share | 1.03 | 1.23 | 0.70 | 1.17 | 0.77 | 0.92 | 1.20 | 1.25 |
| Cash from operations | $448.0m | $359.0m | $517.0m | $418.0m | $378.0m | $382.0m | $506.0m | $395.0m |
| Capital spending | −$54.0m | −$36.0m | −$151.0m | −$127.0m | −$80.0m | −$47.0m | −$84.0m | −$27.0m |
| Free cash flow | $394.0m | $323.0m | $366.0m | $291.0m | $298.0m | $335.0m | $422.0m | $368.0m |
| Total assets | $22.80bn | $22.72bn | $23.09bn | $23.49bn | $22.87bn | $22.18bn | $21.37bn | $21.72bn |
| Cash and short-term investments | $410.0m | $424.2m | $591.9m | $1.29bn | $556.9m | $1.38bn | $525.5m | $569.0m |
| Debt | $7.48bn | $7.47bn | $7.52bn | $8.11bn | $7.57bn | $7.18bn | $6.20bn | $6.45bn |
| Shareholders' equity | $12.62bn | $12.67bn | $12.70bn | $12.76bn | $12.53bn | $12.40bn | $12.47bn | $12.37bn |
Financial ratios
Data as of 28 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 61.6% | 71.5% | 71.8% | 70.9% | 71.3% | 70.2% |
| Operating margin | 13.7% | 16.7% | 17.3% | 10.0% | 12.6% | 1.4% |
| Net margin | 8.6% | 11.8% | 13.8% | 3.3% | 5.9% | -2.3% |
| Return on equity | 5.6% | 7.2% | 8.2% | 1.9% | 3.2% | -1.1% |
| Return on assets | 3.1% | 4.2% | 4.8% | 1.1% | 1.7% | -0.6% |
| Free cash flow yield | 10.7% | 10.2% | 10.4% | 7.7% | 8.7% | 6.9% |
| Revenue growth | 7.2% | 3.8% | 6.5% | 1.6% | 11.4% | -23.2% |
| Earnings growth | -22.0% | -11.7% | 342.5% | -42.4% | -389.1% | -112.3% |
| Current ratio | 1.98x | 1.91x | 1.61x | 1.88x | 1.41x | 1.99x |
| Debt to equity | 0.59x | 0.50x | 0.47x | 0.47x | 0.56x | 0.67x |
| Equity ratio | 55.0% | 58.4% | 58.1% | 57.1% | 54.0% | 49.9% |
| Interest coverage | 3.84x | 5.90x | 6.35x | 4.23x | 4.13x | 0.39x |
| R&D as a share of sales | 5.6% | 5.7% | 6.2% | 5.9% | 6.4% | 5.3% |
| Buybacks as a share of market value | 0.9% | 4.2% | 0.6% | -0.4% | 0.2% | -0.7% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 5.9% | 6.1% | 3.2% |
| Operating income | 17.3% | 68.3% | 9.2% |
| Net income | 45.0% | — | 17.0% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 66.4% | 68.7% | 69.4% | 70.1% |
| Operating margin | 15.1% | 14.5% | 12.3% | 10.6% |
| Net margin | 10.1% | 9.5% | 7.2% | 7.6% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 25.4 | 23.4 | 24.8 | 115.6 | 66.1 | -232.2 | 27.5 | -56.3 | 13.6 | 68.3 |
| Price to sales | 2.2 | 2.8 | 3.4 | 3.9 | 3.9 | 5.3 | 3.9 | 2.7 | 3.2 | 2.7 |
Market value over time
31 Oct 2016 to 25 Sept 2026, in USD
$20.75bn$17.55bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | -15% | -12% | -4% | 5% | -20% | -1% | 48% | -16% | 19% | 0% |
Dividends and splits
Per share, in the currency the company pays
Paid for 14 years. Last went ex-dividend on 30 Sept 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.72 | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.